Data and Dosing on Sublingual Delivery of Semaglutide
Featured Videos
•
1h 21m
Download Handouts: https://bit.ly/48Q3kWG
Are you curious about the latest advancements in the sublingual delivery of semaglutide? Join us for an insightful and informative FREE webinar led by PCCA Chief Scientific Officer Gus Bassani, PharmD, PCCA Director of Research & Development Daniel Banov, MS, RPh, and PCCA Clinical Compounding Pharmacist Sebastian Denison, RPh.
What you’ll learn:
Latest Findings: Discover groundbreaking pharmacokinetic study results highlighting the advantages of sublingual delivery, including less variability in blood levels and improved bioavailability.
Effective Dosing Strategies: Receive practical guidance on dosing strategies and formulations designed for optimal patient outcomes.
Weight Management Support: Explore supplements that complement semaglutide for effective weight management.
Beyond Semaglutide: Gain insights into additional applications of SubMagna™ SL HMW technology beyond semaglutide.
Up Next in Featured Videos
-
Introduction to Gut Health and Autoim...
Run time: 1 hour 33 minutes
Download Handout: https://bit.ly/47M8DFqThis presentation will evaluate the relationship between gut, hormones, and autoimmune conditions. Dr. Berkson will discuss immune response to invaders and examples of common insults. She will describe the anatomy of the gut an...
-
Semaglutide Sublingually: Clinical Ap...
Watch this comprehensive, FREE webinar to learn from your peers about compounded sublingual semaglutide. During this panel session, two PCCA member pharmacists — who are successfully compounding sublingual semaglutide for their patients — will address the common questions many have been asking:
•... -
Preparing for USP Compliance Webinar
Download Handouts: https://bit.ly/46usJmd
Is your pharmacy USP compliance ready?
PCCA Clinical Compounding Pharmacist Matt Lester, RPh, MBA, will help you get there during this FREE webinar, where he’ll discuss the critical USP 795 and USP 800 updates going into effect November 1, 2023.
Matt w...
